{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 8 September 2009\par}
{\pard\f0\sl360\fs22\b Roche announces new Corporate Executive Committee\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire \u8211? Pascal Soriot appointed COO Pharma Division and Daniel O\u8217?Day appointed COO Diagnostics Division \u8211? Jean-Jacques Garaud and Dan Zabrowski to become Members of Enlarged Executive Committee \u8211? Ian Clark appointed CEO Genentech\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 At the end of 2009 William M. Burns (62), CEO Pharma Division, Juergen Schwiezer (65), CEO Diagnostics Division, and Jonathan Knowles (62), Head Group Research, will resign from the Corporate Executive Committee. Juergen Schwiezer and Jonathan Knowles will retire, while William M. Burns, as announced previously, will be proposed as a Member of the Roche Board at the Annual Shareholder Meeting 2010.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 William M. Burns started his career in 1986 with Roche UK. He has been a Member of the Corporate Executive Committee for ten years, thereof eight years as Head Pharma Division. Juergen Schwiezer joined Boehringer Mannheim in 1976 and was appointed Head of its Executive Committee in 1995. He became a Member of the Executive Committee Roche Germany in 1998 and was heading the Diagnostics Division as Member of the Roche Corporate Executive Committee since 2008. Prof. Jonathan Knowles was appointed Head Roche Research in 1997 and has been a Member of the Corporate Executive Committee since 1998.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Franz B. Humer, Chairman of the Roche Group, said: \u8222?William M. Burns, Jonathan Knowles and Juergen Schwiezer have significantly shaped Roche\u8217?s successful development over many years. All three have been instrumental in driving the Group\u8217?s overall success. We are deeply grateful for their tremendous contribution throughout their distinguished careers.\u8221?\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 The Board of Directors has made the following appointments, effective 1 January 2010:\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Pascal Soriot (50), currently CEO Genentech and Member of the Corporate Executive Committee, is appointed Chief Operating Officer (COO) Pharma Division and assumes global responsibility for Pharma operations. These include commercial operations worldwide, global marketing, production, development and registration.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Jean-Jacques Garaud (54), currently Head Pharma Development, is appointed Member of the Enlarged Executive Committee and assumes responsibility for Roche Pharma Research and Early Development.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Dan Zabrowski (50), Head Pharma Partnering, is also appointed Member of the Enlarged Executive Committee.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 As announced previously, Richard Scheller is a Member of the Enlarged Executive Committee. Based in San Francisco, he is responsible for Genentech Research and Early Development, which is managed as an independent unit.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Jean-Jacques Garaud, Richard Scheller and Dan Zabrowski report to Severin Schwan.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Daniel O\u8217?Day (45), currently Head Roche Molecular Diagnostics, is appointed Chief Operating Officer (COO) Diagnostics Division and Member of the Executive Committee. Burkhard Piper, Head Roche Diabetes Care, reports to Daniel O\u8217?Day.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Ian Clark (49), currently Head Global Product Strategy Pharma, will succeed Pascal Soriot as CEO Genentech. He will report to Pascal Soriot and will be based in South San Francisco.\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Franz B. Humer, Chairman of the Roche Group commented: \u8222?We are proud to complement the Corporate Executive Committee with internal appointments having such an impressive track record. With this strong leadership team Roche will continue to be successful in the years ahead!\u8221?\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Severin Schwan, CEO of the Roche Group, said: \u8222?Following the conclusion of the Genentech integration we will continue to bring innovative healthcare solutions to patients worldwide through a diversity of research approaches and through efficient global development and commercialization. This broadened and younger Corporate Executive Committee will continue to drive Roche\u8217?s long-term vision as the world\u8217?s leading biotech company.\u8220?\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Effective 1 January 2010 Roche\u8217?s Corporate Executive Committee (CEC) will be composed as follows: \par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 \par}
{\pard
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl  \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Severin Schwan \cell
\pard\intbl Chief Executive Officer \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Erich Hunziker \cell
\pard\intbl Chief Financial Officer and Deputy Head of the CEC \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Pascal Soriot \cell
\pard\intbl COO Pharma Division \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Daniel O\u8217?Day \cell
\pard\intbl COO Diagnostics Division \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Silvia Ayyoubi \cell
\pard\intbl Head Human Resources \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Gottlieb Keller \cell
\pard\intbl General Counsel \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl   \cell
\pard\intbl  \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Jean-Jacques Garaud* \cell
\pard\intbl Head Roche Pharma Research & Early Development \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Richard Scheller* \cell
\pard\intbl Head Genentech Research & Early Development \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Dan Zabrowski* \cell
\pard\intbl Head Pharma Partnering \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Osamu Nagayama* \cell
\pard\intbl President and CEO Chugai Pharma \cell
\row
\trowd\trgaph100\cellx4800\cellx9600
\pard\intbl Per-Olof Attinger* \cell
\pard\intbl Head Communications \cell
\row
}
{\pard\f0\li0\ri0\sa360\sl360\fs22 \par}
{\pard\f0\li0\ri0\sa360\sl360\fs18 * Member of the Enlarged Corporate Executive Committee\par}
{\pard\f0\sl360\fs22\b About Roche \par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world\u8217?s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche\u8217?s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80\u8217?000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.\par}
{\pard\f0\sa120\sl360\fs30\i Additional information \par}
{\pard\f0\li440\ri0\sl360\fs22 - Organisation chart ( http://www.roche.com/orgchart_090908.pdf)\par}
{\pard\f0\li440\ri0\sl360\fs22 - CV Jean-Jacques Garaud ( http://www.roche.com/cv_garaud_090908.pdf)\par}
{\pard\f0\li440\ri0\sl360\fs22 - CV Daniel O\u8217?Day ( http://www.roche.com/cv_oday_090908.pdf)\par}
{\pard\f0\li440\ri0\sl360\fs22 - CV Pascal Soriot ( http://www.roche.com/cv_soriot_090908.pdf)\par}
{\pard\f0\li440\ri0\sl360\fs22 - CV Dan Zabrowski ( http://www.roche.com/cv_zabrowski_090908.pdf)\par}
{\pard\f0\li440\ri0\sl360\fs22 - CV Ian T. Clark ( http://www.roche.com/cv_clark.pdf)\par}\line 
{\pard\f0\li0\ri0\sa360\sl360\fs22 \par}
{\pard\f0\li440\ri0\sl360\fs22 - Picture Jean-Jacques Garaud ( http://www.roche.com/garaud_full.jpg)\par}
{\pard\f0\li440\ri0\sl360\fs22 - Picture Daniel O'Day ( http://www.roche.com/oday_full.jpg)\par}
{\pard\f0\li440\ri0\sl360\fs22 - Picture Pascal Soriot ( http://www.roche.com/ec-soriot-big-2.jpg)\par}
{\pard\f0\li440\ri0\sl360\fs22 - Picture Dan Zabrowski ( http://www.roche.com/zabrowski_full.jpg)\par}
{\pard\f0\li440\ri0\sl360\fs22 - Picture Ian T. Clark ( http://www.roche.com/clark_med.jpg)\par}\line 
{\pard\f0\li0\ri0\sa360\sl360\fs22 \par}
{\pard\f0\li440\ri0\sl360\fs22 - Spanish PDF ( http://www.roche.com/med-cor-2009-09-08-sp.pdf)\par}
{\pard\f0\li440\ri0\sl360\fs22 - French PDF ( http://www.roche.com/med-cor-2009-09-08-f.pdf)\par}\line 

{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}